AbbVie is ditching work on all the alpha V beta 6 (αvβ6) inhibitors that it paid $20 million to license from Morphic Therapeutic in 2020. The Big Pharma is culling the work because of a suspected on-target "safety signal" from preclinical testing.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,